retatrutide clinical trials sign up Retatrutide, Eli Lilly's next generation of weight loss injections, showed dramatic results in trials, with patients losing an average of to 71.2 pounds, or 28.7% of their body weight. Eli Retatrutide How to use it,

Kaplan cautioned, however, that it has potentially serious side effects, such as increasing the risk of heart rhythm problems in patients with preexisting heart disease

A 2025 narrative review reached comparable conclusions on the compound's positioning within the broader incretin-class research peptide spectrum (PMID 40563436)

Patients will often begin to observe weight loss effects over the first several weeks as the dosage is scaled

Until similar data exists for Retatrutide, there remains an open question about its cardiovascular safety and potential benefit, particularly given the theoretical cardiovascular considerations around glucagon receptor activation